Clinical trials
Trial starts, readouts, holds and designs.
Stories
-
AbbVie announces data to be presented at 2026 ESMO Congress
AbbVie today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology Congress in Madrid, Spain. The presentations cover investigational assets such as Temab-A, ABBV-706, ABBV-969, ABBV-1480, alveltamig, EmrelisTM and Elahere.
-
Vertex posts Phase 3 ELX/TEZ/IVA study results in infants with cystic fibrosis
Vertex Pharmaceuticals Incorporated posted results of a Phase 3 open-label study of ELX/TEZ/IVA in cystic fibrosis participants 12 to less than 24 months of age. The study enrolled 67 participants.
-
ACADIA posts Phase 3 carbetocin nasal spray results in Prader-Willi syndrome
ACADIA Pharmaceuticals Inc. posted results of a 12-week Phase 3 study of carbetocin nasal spray against placebo in hyperphagia in Prader-Willi syndrome. The study enrolled 175 participants.
-
Lilly posts Phase 3 results for lebrikizumab in atopic dermatitis
Eli Lilly’s completed Phase 3 study enrolled 301 participants with moderate-to-severe atopic dermatitis. The registry reports Week 16 EASI-75 response rates across the treatment groups, with results first posted on 2026-10-16.
-
Eli Lilly posts Phase 3 orforglipron results against dapagliflozin
Eli Lilly posted ACHIEVE-2 results on ClinicalTrials.gov on 2026-10-16. The record reports Week 40 blood-sugar and body-weight measures in 962 adults with type 2 diabetes taking metformin.
-
AstraZeneca registers Phase 3 trial of durvalumab and FLOT in Chinese gastric cancer patients
The study, titled MATTERHORN-CN, plans to enroll 140 participants and plans to start on November 30, 2026. It compares neoadjuvant-adjuvant durvalumab plus FLOT chemotherapy to placebo plus FLOT in resectable gastric and gastroesophageal junction cancer.
-
Eli Lilly posts results of Phase 3 lebrikizumab trial in atopic dermatitis
Results for the Phase 3 trial of lebrikizumab with or without topical corticosteroid treatment in participants with moderate-to-severe atopic dermatitis were first posted on ClinicalTrials.gov on October 16, 2026. The completed study enrolled 301 participants and began on April 24, 2024.
-
Eli Lilly posts results of Phase 3 orforglipron vs dapagliflozin study
The company posted results for the ACHIEVE-2 study, a Phase 3, randomized, open-label trial that enrolled 962 participants with type 2 diabetes. The study compared once-daily oral orforglipron (LY3502970) with dapagliflozin and completed primary data collection on September 26, 2025.
-
Nektar posts results of Phase 2/3 NKTR-255 trial in relapsed/refractory large B-cell lymphoma
Results for the study were first posted on ClinicalTrials.gov on October 16, 2026. The terminated study enrolled 15 participants and had a primary completion date of May 22, 2024.
-
TETON-2 results posted: inhaled treprostinil and lung function in idiopathic pulmonary fibrosis
On October 15, 2026, United Therapeutics' registry entry for the Phase 3 TETON-2 trial posted results. It reports a 95.6 mL difference in FVC change at Week 52 against placebo.
-
AERIFY-1 results posted: itepekimab and COPD exacerbations in former smokers
On October 15, 2026, Sanofi's registry entry for the Phase 3 AERIFY-1 trial posted results. Both itepekimab doses lowered the annualized rate of moderate or severe exacerbations against placebo.
-
Pfizer registers Phase 3 trial of PF-08653944 in Chinese adults with overweight or obesity
The study plans to enroll an estimated 432 participants and compares berobenatide (PF-08653944) with placebo. It is scheduled to start on October 15, 2026, with primary completion expected on June 6, 2028.